問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of Pediatrics

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

林鴻銓Lin, Horng-Chyuan
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林鴻銓

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

List

39Cases

2025-06-16 - 2029-09-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2014-12-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-04-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-07-01 - 2021-07-22

Phase III

A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma.

  • Condition/Disease

    Asthma

  • Test Drug

    Benralizumab

Participate Sites
4Sites

Recruiting4Sites

2021-10-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2014-09-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-08-01 - 2011-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-03-01 - 2017-07-31

Phase II

A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

  • Condition/Disease

    Influenza A

  • Test Drug

    MHAA4549A

Participate Sites
5Sites

Study ended4Sites

歐聰億
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2011-01-01 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB